const topic14 = {
  id: 'topic-14',
  mcqs: ['mcq-2'],
  number: 14,
  title: 'Primary hemostasis',
  subtitle: 'The initial response to vascular injury involving vasoconstriction and platelet plug formation, representing the first line of defense against bleeding through the formation of a white thrombus.',
  learningObjectives: [
    {
      id: 'lo-1',
      isCritical: false,
      title: 'What is the difference between hemostasis and blood coagulation? Compare the white and the red thrombus.',
      keyPoints: [
        'Hemostasis: Process stopping bleeding after vascular injury; includes vasoconstriction, platelet plug formation, and blood coagulation',
        'Blood coagulation (secondary hemostasis): Specific phase forming fibrin mesh to stabilize platelet plug via cascade of clotting factors',
        'White thrombus (platelet thrombus): Formed during primary hemostasis; composition mainly platelets and fibrin with few RBCs; pale appearance due to high platelet content',
        'Red thrombus (coagulation thrombus): Formed during secondary hemostasis; composition fibrin mesh trapping many RBCs and some platelets; dark red appearance',
        'White thrombus mechanism: Platelets adhere to exposed collagen and aggregate; little RBC trapping due to fast blood flow',
        'Red thrombus mechanism: Coagulation cascade produces fibrin mesh that traps RBCs',
        'Both serve hemostatic balance along with defense against infection and tissue repair'
      ],
      officialDefinitions: [
        'Hemostasis: the process by which the body stops bleeding after a vascular injury. It encompasses a series of steps involving vasoconstriction, platelet plug formation, and the subsequent blood coagulation process.',
        'Blood coagulation: a specific phase within the hemostasis process where a fibrin mesh is formed to stabilize the platelet plug. This involves a cascade of clotting factors that ultimately convert fibrinogen into fibrin, leading to clot formation.',
        'White Thrombus (Platelet Thrombus) Composition: Mainly platelets and fibrin, with few red blood cells. Mechanism: Forms during primary hemostasis. Platelets adhere to exposed subendothelial collagen and aggregate. Little RBC trapping due to fast blood flow. Appearance: Pale or white due to high platelet content.',
        'Red Thrombus (Coagulation Thrombus) Composition: Fibrin mesh trapping many red blood cells, some platelets. Mechanism: Forms during secondary hemostasis. Coagulation cascade → fibrin mesh formation → traps RBCs. Appearance: Dark red due to rich RBC content.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'Hemostasis is the process by which the body stops bleeding after vascular injury through vasoconstriction, platelet plug formation, and blood coagulation. Blood coagulation is a specific phase within hemostasis where a fibrin mesh is formed to stabilize the platelet plug through a cascade of clotting factors that convert fibrinogen into fibrin.' },
          { type: 'paragraph', content: 'The white thrombus forms during primary hemostasis and consists mainly of platelets and fibrin with few red blood cells, appearing pale due to high platelet content. It forms when platelets adhere to exposed subendothelial collagen and aggregate, with little RBC trapping due to fast blood flow.' },
          { type: 'paragraph', content: 'The red thrombus forms during secondary hemostasis and consists of a fibrin mesh trapping many red blood cells and some platelets, appearing dark red. It forms through the coagulation cascade producing fibrin mesh that efficiently traps RBCs.' }
        ],
        raw: 'Hemostasis is the process by which the body stops bleeding after vascular injury through vasoconstriction, platelet plug formation, and blood coagulation. Blood coagulation is a specific phase within hemostasis where a fibrin mesh is formed to stabilize the platelet plug through a cascade of clotting factors that convert fibrinogen into fibrin. The white thrombus forms during primary hemostasis and consists mainly of platelets and fibrin with few red blood cells, appearing pale due to high platelet content. It forms when platelets adhere to exposed subendothelial collagen and aggregate, with little RBC trapping due to fast blood flow. The red thrombus forms during secondary hemostasis and consists of a fibrin mesh trapping many red blood cells and some platelets, appearing dark red. It forms through the coagulation cascade producing fibrin mesh that efficiently traps RBCs.'
      },
      audioUrl: '/Audio/Topic-014/LO-01.mp3'
    },
    {
      id: 'lo-2',
      isCritical: false,
      title: 'Describe the basic steps of thrombopoesis.',
      keyPoints: [
        'Thrombopoiesis: Platelet formation from megakaryocytes in bone marrow',
        'Step 1 - HSC differentiation: Pluripotent hematopoietic stem cells give rise to CFU-Me (Colony Forming Unit-Megakaryocyte)',
        'Step 2 - Megakaryoblast development: CFU-Me differentiates into megakaryoblasts, earliest committed precursors',
        'Step 3 - Megakaryocyte formation: Megakaryoblasts mature into large multinucleated megakaryocytes via endomitosis (DNA replication without cytokinesis)',
        'Step 4 - Thrombopoietin regulation: Glycoprotein hormone from liver and kidney regulates megakaryocyte proliferation and maturation; binds to receptors on megakaryocytes',
        'Step 5 - Platelet release: Megakaryocytes extend proplatelets into bone marrow blood vessels; proplatelets fragment releasing individual platelets (cell fragments, no nucleus)',
        'Step 6 - Circulation: Platelets circulate 7-10 days; thrombopoietin feedback regulates production (low platelet count increases free thrombopoietin stimulating megakaryocytes)'
      ],
      officialDefinitions: [
        'Thrombopoiesis: the process of platelet formation from megakaryocytes within the bone marrow.',
        'Hematopoietic Stem Cell Differentiation: The process begins with pluripotent hematopoietic stem cells (HSCs) in the bone marrow, which give rise to a colony-forming unit called CFU-Me (Colony Forming Unit-Megakaryocyte).',
        'Development to Megakaryoblast: CFU-Me differentiates into megakaryoblasts, which are the earliest committed precursors in platelet production.',
        'Formation of Megakaryocytes: The megakaryoblasts mature into megakaryocytes, which are large, multinucleated cells due to repeated DNA replication without cytokinesis (a process called endomitosis). These cells can be found in the bone marrow and are characterized by their large size and extensive cytoplasm.',
        'Influence of Thrombopoietin: Thrombopoietin, a glycoprotein hormone mainly produced by the liver and kidney, plays a critical role in regulating the proliferation and maturation of megakaryocytes. Thrombopoietin binds to receptors on the surface of megakaryocytes and circulating platelets, influencing their development and subsequent platelet formation. Thrombopoietin in plasma binds to receptors on the surface of circulating platelets; the remaining, unbound thrombopoietin in plasma is available to promote megakaryocyte proliferation. Thus, when the platelet count drops, increased plasma levels of free thrombopoietin stimulate megakaryocytes.',
        'Release of Platelets: Mature megakaryocytes extend cytoplasmic protrusions called proplatelets into the blood vessels within the bone marrow. These proplatelets fragment into smaller pieces, releasing individual platelets into the circulation. Platelets are essentially cell fragments, not full cells, and are devoid of a nucleus.',
        'Platelet Circulation: Once released, platelets circulate in the blood for an average lifespan of 7-10 days. They play a critical role in hemostasis by adhering to sites of vascular injury, aggregating, and forming a platelet plug to prevent bleeding.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'Thrombopoiesis is the process of platelet formation from megakaryocytes in the bone marrow.' },
          {
            type: 'steps',
            intro: 'The basic steps include:',
            items: [
              'Pluripotent hematopoietic stem cells differentiate into colony forming unit megakaryocyte, or CFU-Me.',
              'CFU-Me differentiates into megakaryoblasts, the earliest committed precursors.',
              'Megakaryoblasts mature into megakaryocytes, large multinucleated cells due to endomitosis, repeated DNA replication without cytokinesis.',
              'Thrombopoietin, a glycoprotein hormone mainly produced by the liver and kidney, regulates megakaryocyte proliferation and maturation by binding to receptors on their surface.',
              'Mature megakaryocytes extend cytoplasmic protrusions called proplatelets into bone marrow blood vessels, which fragment releasing individual platelets into circulation. Platelets are cell fragments without a nucleus.',
              'Platelets circulate for seven to ten days. When platelet count drops, increased plasma levels of free thrombopoietin stimulate megakaryocytes to produce more platelets.'
            ]
          }
        ],
        raw: 'Thrombopoiesis is the process of platelet formation from megakaryocytes in the bone marrow. First, pluripotent hematopoietic stem cells differentiate into colony forming unit megakaryocyte, or CFU-Me. Second, CFU-Me differentiates into megakaryoblasts, the earliest committed precursors. Third, megakaryoblasts mature into megakaryocytes, large multinucleated cells due to endomitosis, repeated DNA replication without cytokinesis. Fourth, thrombopoietin, a glycoprotein hormone mainly produced by the liver and kidney, regulates megakaryocyte proliferation and maturation by binding to receptors on their surface. Fifth, mature megakaryocytes extend cytoplasmic protrusions called proplatelets into bone marrow blood vessels, which fragment releasing individual platelets into circulation. Platelets are cell fragments without a nucleus. Sixth, platelets circulate for seven to ten days. When platelet count drops, increased plasma levels of free thrombopoietin stimulate megakaryocytes to produce more platelets.'
      },
      audioUrl: '/Audio/Topic-014/LO-02.mp3'
    },
    {
      id: 'lo-3',
      isCritical: false,
      title: 'What is the normal value of thrombocyte count?',
      keyPoints: [
        'Normal platelet count: 150,000-300,000 per microliter of blood',
        'Critical reference value for exam',
        'Thrombocytopenia: Platelet count below 150,000/μl; increased bleeding risk',
        'Thrombocytosis: Platelet count above 300,000/μl; increased clotting risk',
        'Measurement methods: Automated cell counters or manual counting using hemocytometer'
      ],
      officialDefinitions: [
        'Normal value of thrombocyte count: 150 000-300 000/μl blood.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'The normal thrombocyte count is 150,000 to 300,000 platelets per microliter of blood. Values below indicate thrombocytopenia with increased bleeding risk, while values above indicate thrombocytosis with increased clotting risk.' }
        ],
        raw: 'The normal thrombocyte count is 150,000 to 300,000 platelets per microliter of blood. Values below indicate thrombocytopenia with increased bleeding risk, while values above indicate thrombocytosis with increased clotting risk.'
      },
      audioUrl: '/Audio/Topic-014/LO-03.mp3'
    },
    {
      id: 'lo-4',
      isCritical: false,
      title: 'Describe the most important morphological features of the thrombocytes, size, types of granules.',
      keyPoints: [
        'Size: Typically 1-3 micrometers in diameter',
        'Lifespan: 5-8 days in circulation',
        'Structure: No nucleus; contain cytoplasmic structures including surface glycoproteins (integrins), actin-myosin cytoskeleton, open canalicular system',
        'Dense granules: Contain ADP, serotonin, adrenaline; function in platelet activation and aggregation',
        'Alpha granules: Contain clotting factors (Factor V, von Willebrand factor), growth factors (PDGF), and proteins (fibronectin, fibrinogen); promote clotting and wound healing',
        'Lysosomes: Contain enzymes for degradation of foreign particles',
        'Additional components: Mitochondria for energy, glycogen as energy source'
      ],
      officialDefinitions: [
        'Size: Typically range from 1-3 µm in diameter.',
        'Lifespan: They have a lifespan of approximately 5-8 days.',
        'Structure: Platelets do not have a nucleus but contain various cytoplasmic structures important for their function. Surface Factors: Include glycoproteins, such as integrins, which play a critical role in platelet adhesion to damaged vessel walls. Cytoskeleton Components: Platelets contain actin and myosin, allowing them to change shape and facilitate contraction during clot formation. Open Canalicular System (OCS): This system allows for the release of stored contents from granules.',
        'Dense Granules: Contents: Include adenosine diphosphate (ADP), serotonin, and adrenaline. Function: Play a key role in platelet activation and aggregation.',
        'Alpha Granules: Contents: Contain clotting factors such as Factor V, von Willebrand factor (VWF), growth factors, and proteins like fibronectin. Function: Involved in promoting clotting and wound healing.',
        'Lysosomes: Contents: Enzymes that help in breaking down foreign particles. Function: Support the degradation of internalized debris or other particles during clot formation.',
        'Mitochondria: Present to provide energy required for various platelet functions.',
        'Glycogen: Serves as an energy source to support platelet metabolism.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'Thrombocytes typically range from one to three micrometers in diameter with a lifespan of five to eight days. Platelets lack a nucleus but contain important cytoplasmic structures.' },
          {
            type: 'list',
            intro: 'Key structural features include:',
            items: [
              'Surface glycoproteins such as integrins for platelet adhesion to damaged vessel walls',
              'Cytoskeleton with actin and myosin, allowing shape changes and contraction during clot formation',
              'Open canalicular system allowing release of stored granule contents'
            ]
          },
          {
            type: 'list',
            intro: 'Platelets contain three main granule types:',
            items: [
              'Dense granules containing adenosine diphosphate, serotonin, and adrenaline for platelet activation and aggregation',
              'Alpha granules containing clotting factors such as Factor V and von Willebrand factor, growth factors like platelet-derived growth factor, and proteins including fibronectin and fibrinogen for promoting clotting and wound healing',
              'Lysosomes containing enzymes for breaking down foreign particles'
            ]
          },
          { type: 'paragraph', content: 'Additionally, platelets contain mitochondria for energy and glycogen as an energy source supporting platelet metabolism.' }
        ],
        raw: 'Thrombocytes typically range from one to three micrometers in diameter with a lifespan of five to eight days. Platelets lack a nucleus but contain important cytoplasmic structures. The surface contains glycoproteins such as integrins for platelet adhesion to damaged vessel walls. The cytoskeleton contains actin and myosin, allowing shape changes and contraction during clot formation. The open canalicular system allows release of stored granule contents. Platelets contain three main granule types. Dense granules contain adenosine diphosphate, serotonin, and adrenaline for platelet activation and aggregation. Alpha granules contain clotting factors such as Factor V and von Willebrand factor, growth factors like platelet-derived growth factor, and proteins including fibronectin and fibrinogen for promoting clotting and wound healing. Lysosomes contain enzymes for breaking down foreign particles. Additionally, platelets contain mitochondria for energy and glycogen as an energy source supporting platelet metabolism.'
      },
      audioUrl: '/Audio/Topic-014/LO-04.mp3'
    },
    {
      id: 'lo-5',
      isCritical: false,
      title: 'Elaborate the role of primary hemostasis, enlist its major processes.',
      keyPoints: [
        'Primary hemostasis: Initial rapid response to vascular injury preventing blood loss through platelet plug formation',
        'Process 1 - Vasoconstriction: Immediate vessel constriction reducing blood flow; mechanisms include local myogenic spasm, endothelin release, thromboxane A2 and serotonin from platelets, nervous reflexes',
        'Process 2 - Platelet adhesion: Platelets adhere to exposed subendothelial collagen via GPIa/IIa and GPVI receptors (direct) or via von Willebrand factor using GPIb/IX/V receptors (indirect, for high shear)',
        'Process 3 - Platelet activation: Morphological changes (pseudopod formation), degranulation releasing ADP, serotonin, calcium, clotting factors, synthesis of thromboxane A2',
        'Process 4 - Platelet aggregation: Platelets link via fibrinogen bridges binding GPIIb/IIIa receptors on adjacent platelets forming platelet plug',
        'Additional roles: Wound healing via growth factor release (PDGF), defense against infection by trapping pathogens',
        'Result: White thrombus formation providing foundation for secondary hemostasis stabilization'
      ],
      officialDefinitions: [
        'Primary hemostasis: a critical initial step in the body\'s response to vascular injury, aiming to quickly prevent blood loss through the formation of a temporary platelet plug. This stage includes multiple coordinated processes that involve platelets and the vessel wall.',
        'Vasoconstriction Initial Reaction: Immediately after vascular injury, the blood vessel constricts to reduce blood flow and minimize blood loss. This step is crucial as it helps limit bleeding and allows time for the subsequent steps of hemostasis. Mechanisms Involved: Local Myogenic Spasm: The direct injury to the smooth muscle cells in the vessel wall triggers an immediate contraction. Release of Vasoconstrictive Substances: Activated platelets and damaged endothelial cells release substances such as thromboxane A2, serotonin, and adrenaline to sustain and enhance the vasoconstriction. Nervous Reflexes: Pain and sensory impulses from the site of injury contribute to the reflex contraction of the vessel. Duration and Significance: The vasoconstriction can last from minutes to hours, depending on the severity of the injury. It creates a conducive environment for the next hemostatic steps by reducing blood flow at the site of damage.',
        'Platelet Adhesion Exposure to Subendothelial Structures: When the endothelium is breached, subendothelial collagen and von Willebrand factor (vWF) become exposed to the bloodstream. Adhesion Process: Platelets adhere to the exposed collagen fibers using glycoprotein receptors (such as GPIb) that bind to vWF (indirect way), which acts as a bridge between platelets and collagen. The glycoprotein that connects collagen to the platelet is GP Ia/IIa and GP VI. Platelet Activation: Upon binding to the subendothelial matrix, platelets undergo activation that triggers several changes in their properties.',
        'Platelet Activation Morphological Changes: Activated platelets swell and extend pseudopods, which increase their surface area and improve their ability to adhere and interact with other platelets. Degranulation (Release of Granule Contents): Alpha Granules: Release clotting factors like fibrinogen, platelet-derived growth factor (PDGF), and von Willebrand factor, contributing to clot formation and vessel repair. Dense Granules: Release substances such as ADP, calcium ions, and serotonin, which further recruit and activate nearby platelets. Synthesis of Thromboxane A2: Thromboxane A2 is a potent vasoconstrictor and platelet activator, synthesized from arachidonic acid within activated platelets. It reinforces vasoconstriction and recruits additional platelets to the site.',
        'Platelet Aggregation Formation of a Platelet Plug: ADP and thromboxane A2 released from activated platelets stimulate the aggregation of more platelets. Platelets link to each other through fibrinogen bridges that bind glycoprotein IIb/IIIa receptors on adjacent platelets. Plug Stability: The initial plug formed is soft and reversible. It effectively seals small injuries to prevent blood loss. However, in larger injuries, this plug needs stabilization through secondary hemostasis (the coagulation cascade) to form a more robust fibrin clot.',
        'Role and Importance of Primary Hemostasis: Primary hemostasis is essential for maintaining hemostatic integrity after minor injuries. The formation of a platelet plug helps to prevent excessive blood loss quickly and forms a foundation for further clot stabilization by secondary hemostasis. This initial response also plays a part in: Wound Healing and Tissue Repair: The growth factors released by platelets stimulate endothelial and smooth muscle cell proliferation, aiding in vessel repair. Defense Against Infection: The aggregation of platelets can trap pathogens, aiding in immune defense.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'Primary hemostasis is the initial response to vascular injury that prevents blood loss through formation of a temporary platelet plug.' },
          {
            type: 'steps',
            intro: 'The major processes include:',
            items: [
              'Vasoconstriction: The injured vessel immediately constricts to reduce blood flow through local myogenic spasm, endothelin release from injured endothelial cells, thromboxane A2 and serotonin from activated platelets, and nervous reflexes.',
              'Platelet adhesion: Platelets adhere to exposed subendothelial collagen using GPIa/IIa and GPVI receptors for direct binding in low shear conditions, or GPIb/IX/V receptors to bind von Willebrand factor in high shear conditions.',
              'Platelet activation: Following adhesion, platelets undergo morphological changes with pseudopod extension, degranulation where alpha granules release clotting factors and growth factors and dense granules release ADP, calcium, and serotonin, and synthesis of thromboxane A2 which enhances vasoconstriction and recruits more platelets.',
              'Platelet aggregation: Activated platelets link through fibrinogen bridges binding GPIIb/IIIa receptors on adjacent platelets, forming a stable platelet plug.'
            ]
          }
        ],
        raw: 'Primary hemostasis is the initial response to vascular injury that prevents blood loss through formation of a temporary platelet plug. The major processes include, first, vasoconstriction, where the injured vessel immediately constricts to reduce blood flow through local myogenic spasm, endothelin release from injured endothelial cells, thromboxane A2 and serotonin from activated platelets, and nervous reflexes. Second, platelet adhesion occurs when platelets adhere to exposed subendothelial collagen using GPIa/IIa and GPVI receptors for direct binding in low shear conditions, or GPIb/IX/V receptors to bind von Willebrand factor in high shear conditions. Third, platelet activation follows adhesion, triggering morphological changes with pseudopod extension, degranulation where alpha granules release clotting factors and growth factors and dense granules release ADP, calcium, and serotonin, and synthesis of thromboxane A2 which enhances vasoconstriction and recruits more platelets. Fourth, platelet aggregation occurs when activated platelets link through fibrinogen bridges binding GPIIb/IIIa receptors on adjacent platelets, forming a stable platelet plug.'
      },
      audioUrl: '/Audio/Topic-014/LO-05.mp3'
    },
    {
      id: 'lo-6',
      isCritical: true,
      title: '>>Explain the adhesion, aggregation and activation of thrombocytes.<< Give some of the molecular mechanisms of these process (von Villebrand factor, the glycoproteins involved in platelet adhesion/aggregation, the mediators, receptors and signal transduction pathways involved in platelet activation).',
      keyPoints: [
        'Adhesion: Platelets bind to exposed subendothelial collagen; direct via GPIa/IIa (integrin α2β1) and GPVI receptors (low shear); indirect via GPIb/IX/V binding to von Willebrand factor attached to collagen (high shear)',
        'von Willebrand factor (vWF): Secreted by endothelial cells; bridges collagen and platelets via GPIb/IX/V receptor; critical for adhesion in high shear stress conditions',
        'Activation mediators: ADP (from dense granules) binds P2Y1 and P2Y12 receptors; thromboxane A2 binds TXA2 receptors; thrombin binds PAR-1 and PAR-4; collagen activates GPIa/IIa and GPVI',
        'Signal transduction: GPCR activation → Gq and Gi proteins activate → PLC-β hydrolyzes PIP2 into IP3 and DAG → IP3 releases Ca2+ from stores → increased Ca2+ exposes GPIIb/IIIa and triggers secretion',
        'Activation consequences: Shape change via actin-myosin, granule secretion, GPIIb/IIIa (integrin αIIbβ3) conformational change and exposure',
        'Aggregation: Activated GPIIb/IIIa receptors bind fibrinogen and vWF creating bridges between adjacent platelets; amplified by ADP and thromboxane A2 recruiting more platelets',
        'Thromboxane A2 synthesis: Arachidonic acid converted by cyclooxygenase to TXA2 (aspirin irreversibly inhibits this); TXA2 promotes vasoconstriction and platelet activation'
      ],
      officialDefinitions: [
        'Adhesion: the initial step when platelets come into contact with the damaged vascular endothelium, especially exposed collagen in the subendothelial layer.',
        'Interaction with Collagen: Platelets use their surface receptors to bind to the exposed collagen at the injury site. The primary receptor involved is GPIa/IIa (integrin α2β1) GP IV, which allows direct attachment to the collagen fibers (Direct way) → for low shear stress (vein).',
        'Role of von Willebrand Factor (vWF): vWF plays a crucial role in stabilizing platelet adhesion, especially under conditions of high shear stress (e.g., in small arteries and arterioles). GPIb/IX/V on the platelet surface binds to vWF, which in turn is attached to the subendothelial collagen. This binding is essential for anchoring the platelets to the site of injury (Indirect way) → for high shear stress (artery). When the endothelium is damaged, the subendothelial matrix, especially collagen, is exposed. vWF binds to the exposed collagen and serves as a bridge between the subendothelial matrix and platelets. The platelet receptor GPIb/IX/V complex binds to vWF, anchoring platelets to the site of vascular injury.',
        'Glycoproteins Involved in Adhesion: GPIb/IX/V: This complex is crucial for platelet adhesion to vWF under high shear conditions. GPIa/IIa (α2β1 integrin): This receptor binds directly to collagen, promoting firm platelet adhesion.',
        'Platelet Morphological Change: Upon contact with the subendothelial matrix, platelets become activated and change shape, forming pseudopods that help them adhere more firmly to the vessel wall and other platelets.',
        'Activation: triggered once platelets adhere to the damaged vessel wall. This leads to a series of intracellular and extracellular events that prepare the platelets for aggregation.',
        'Initiating Mediators and Receptors: ADP is released from platelet dense granules and binds to P2Y1 and P2Y12 receptors on the platelet surface, initiating intracellular signaling cascades. Thromboxane A2 (TXA2), synthesized by activated platelets, binds to TXA2 receptors, amplifying the activation response. Thrombin, a potent platelet activator, binds to protease-activated receptors (PARs), particularly PAR-1 and PAR-4. Collagen interaction with GPIa/IIa and GPVI initiates direct platelet activation.',
        'Signal Transduction Pathways: Binding of platelets to collagen and direct or indirect way triggers intracellular signaling pathways, activating phospholipase C and other enzymes that increase cytoplasmic calcium levels. G-protein coupled receptor (GPCR) activation: Engagement of ADP and TXA2 receptors activates Gq and Gi proteins.',
        'Phospholipase C (PLC) Pathway: Activated Gq protein stimulates PLC-β, which hydrolyzes PIP2 into IP3 and DAG. IP3 increases intracellular Ca²⁺ levels by promoting its release from the dense tubular system. DAG activates protein kinase C (PKC), leading to phosphorylation of downstream proteins involved in secretion and shape change.',
        'Calcium as a Central Signal: The rise in Ca²⁺ triggers conformational changes that expose GPIIb/IIIa (αIIbβ3 integrin), essential for platelet aggregation. High Ca²⁺ levels activate various enzymes and proteins, facilitating granule secretion and activation of additional platelets.',
        'cAMP and cGMP Modulation: Prostacyclin (PGI2) and nitric oxide (NO) produced by endothelial cells increase cAMP and cGMP levels, respectively, through activation of adenylyl cyclase and guanylyl cyclase. Elevated cAMP and cGMP promote Ca²⁺ efflux via Ca-ATPase, inhibiting platelet activation and maintaining vascular integrity.',
        'Release of Granule Contents: Activated platelets release the contents of their dense granules (containing ADP, serotonin, and calcium) and α-granules (containing clotting factors, growth factors, and vWF). ADP and thromboxane A2 (TXA2), synthesized during platelet activation, are essential for recruiting and activating more platelets.',
        'Expression of GPIIb/IIIa Receptors: Platelet activation causes a conformational change in GPIIb/IIIa (integrin αIIbβ3) receptors, enabling them to bind fibrinogen and vWF, which are crucial for aggregation.',
        'Synthesis of Thromboxane A2: Arachidonic acid in the platelet membrane is converted into TXA2, a potent vasoconstrictor and promoter of platelet aggregation.',
        'Aggregation: the process where platelets bind to each other to form a cohesive platelet plug.',
        'Fibrinogen as a Bridge: Activated GPIIb/IIIa receptors on adjacent platelets bind to fibrinogen molecules, which act as bridges between platelets. This cross-linking effect results in platelet aggregation. Fibrinogen acts as a ligand that connects adjacent platelets through binding with GPIIb/IIIa on each platelet.',
        'Role of ADP and TXA2: Released ADP binds to P2Y12 receptors on platelets, amplifying the activation process and stabilizing the platelet aggregate. TXA2 also acts in an autocrine and paracrine manner to enhance aggregation.',
        'Stable Platelet Plug Formation: The aggregated platelets form a temporary but solid plug at the site of injury. This plug is stabilized when the secondary hemostasis (coagulation cascade) generates fibrin, which reinforces the platelet mass.',
        'Amplification by Secreted Mediators: ADP and TXA2 are secreted by activated platelets, recruiting additional platelets to the injury site. Thrombin not only activates platelets but also catalyzes the formation of fibrin from fibrinogen, stabilizing the platelet plug.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: '>>Adhesion is the initial step where platelets bind to exposed subendothelial collagen at vascular injury sites. Direct adhesion occurs via GPIa/IIa, integrin alpha-two beta-one, and GPVI receptors binding collagen in low shear stress conditions like veins. Indirect adhesion occurs via GPIb/IX/V receptors binding von Willebrand factor attached to collagen, essential in high shear stress conditions like arteries.<<', critical: true },
          { type: 'paragraph', content: '>>Activation follows adhesion and involves multiple mediators and signaling pathways. ADP released from dense granules binds P2Y1 and P2Y12 receptors, thromboxane A2 binds TXA2 receptors, thrombin binds protease-activated receptors PAR-1 and PAR-4, and collagen activates GPIa/IIa and GPVI. These activate G-protein coupled receptor pathways where Gq and Gi proteins stimulate phospholipase C beta, hydrolyzing PIP2 into IP3 and DAG. IP3 increases intracellular calcium by releasing it from internal stores, while DAG activates protein kinase C. Elevated calcium triggers conformational changes exposing GPIIb/IIIa receptors, morphological changes producing pseudopods, degranulation releasing ADP, calcium, serotonin, clotting factors, and synthesis of thromboxane A2 from arachidonic acid via cyclooxygenase.<<', critical: true },
          { type: 'paragraph', content: '>>Aggregation is the final step where activated GPIIb/IIIa receptors, integrin alpha-IIb beta-three, bind fibrinogen and von Willebrand factor molecules that bridge adjacent platelets together, amplified by secreted ADP and thromboxane A2 recruiting additional platelets to form a stable platelet plug.<<', critical: true }
        ],
        raw: '>>Adhesion is the initial step where platelets bind to exposed subendothelial collagen at vascular injury sites. Direct adhesion occurs via GPIa/IIa, integrin alpha-two beta-one, and GPVI receptors binding collagen in low shear stress conditions like veins. Indirect adhesion occurs via GPIb/IX/V receptors binding von Willebrand factor attached to collagen, essential in high shear stress conditions like arteries. Activation follows adhesion and involves multiple mediators and signaling pathways. ADP released from dense granules binds P2Y1 and P2Y12 receptors, thromboxane A2 binds TXA2 receptors, thrombin binds protease-activated receptors PAR-1 and PAR-4, and collagen activates GPIa/IIa and GPVI. These activate G-protein coupled receptor pathways where Gq and Gi proteins stimulate phospholipase C beta, hydrolyzing PIP2 into IP3 and DAG. IP3 increases intracellular calcium by releasing it from internal stores, while DAG activates protein kinase C. Elevated calcium triggers conformational changes exposing GPIIb/IIIa receptors, morphological changes producing pseudopods, degranulation releasing ADP, calcium, serotonin, clotting factors, and synthesis of thromboxane A2 from arachidonic acid via cyclooxygenase. Aggregation is the final step where activated GPIIb/IIIa receptors, integrin alpha-IIb beta-three, bind fibrinogen and von Willebrand factor molecules that bridge adjacent platelets together, amplified by secreted ADP and thromboxane A2 recruiting additional platelets to form a stable platelet plug.<<'
      },
      audioUrl: '/Audio/Topic-014/LO-06.mp3'
    },
    {
      id: 'lo-7',
      isCritical: false,
      title: 'What is the role of the endothelial cells in the regulation of hemostasis?',
      keyPoints: [
        'Anti-thrombotic properties (intact endothelium): Prostacyclin (PGI2) increases cAMP decreasing Ca2+ inhibiting platelet activation; nitric oxide (NO) increases cGMP causing vasodilation and inhibiting platelet adhesion',
        'Heparan sulfate: Expressed on endothelial surface; binds and enhances antithrombin III activity inhibiting thrombin and factor Xa',
        'Thrombomodulin-Protein C system: Thrombomodulin binds thrombin changing its function; thrombin-thrombomodulin complex activates protein C; activated protein C with protein S cofactor degrades factors Va and VIIIa limiting coagulation',
        'Pro-thrombotic activities (damaged endothelium): Release von Willebrand factor from Weibel-Palade bodies facilitating platelet adhesion via GPIb/IX/V; express P-selectin recruiting platelets and leukocytes',
        'Endothelin release: Potent vasoconstrictor reducing blood flow limiting blood loss',
        'Glycocalyx: Carbohydrate-rich surface layer preventing excessive platelet and leukocyte adhesion; contains heparan sulfate enhancing antithrombin III activity',
        'Balance: Endothelial cells maintain hemostatic balance between pro-coagulating and anti-coagulating activities'
      ],
      officialDefinitions: [
        'Endothelial cells: play a crucial role in the regulation of hemostasis by balancing pro-thrombotic and anti-thrombotic factors to maintain vascular homeostasis.',
        'Prevention of Platelet Adhesion and Activation (Anti-thrombotic Properties) Production of Prostacyclin (PGI2): Endothelial cells synthesize and release prostacyclin (PGI2), which binds to receptors on platelets and increases intracellular cAMP levels. Elevated cAMP leads to decreased intracellular Ca²⁺ levels, inhibiting platelet activation and aggregation.',
        'Nitric Oxide (NO) Production: NO is produced by endothelial nitric oxide synthase (eNOS) and diffuses to the underlying smooth muscle and platelets. NO increases cGMP levels, which activates protein kinase G (PKG), leading to vasodilation and inhibition of platelet adhesion and aggregation.',
        'Surface Expression of Heparan Sulfate: Endothelial cells express heparan sulfate, which binds and enhances the activity of antithrombin III (ATIII), an inhibitor of thrombin and factor Xa, preventing clot formation.',
        'Thrombomodulin and Protein C Activation: Thrombomodulin is a receptor expressed on the surface of endothelial cells that binds thrombin, altering its substrate specificity. The thrombin-thrombomodulin complex activates protein C, which, in the presence of protein S, degrades factors Va and VIIIa, reducing thrombin formation and limiting coagulation.',
        'Pro-thrombotic Activities (When Endothelial Integrity is Disrupted) Release of von Willebrand Factor (vWF): Endothelial cells store vWF in Weibel-Palade bodies and release it into the bloodstream when there is vascular injury. vWF binds to exposed collagen and facilitates the adhesion of platelets through GPIb/IX/V on the platelet surface.',
        'P-selectin and Adhesion Molecules: Endothelial cells express P-selectin and other adhesion molecules that help recruit platelets and leukocytes to the site of injury, contributing to hemostatic plug formation.',
        'Release of Endothelin: Endothelin is a potent vasoconstrictor released by endothelial cells that helps reduce blood flow to the damaged area, limiting blood loss.',
        'The glycocalyx: a carbohydrate-rich layer on the surface of endothelial cells that plays a crucial role in regulating hemostasis. It serves as a protective barrier, preventing excessive adhesion of platelets and leukocytes to the endothelial surface, thereby reducing the risk of unnecessary clot formation. The glycocalyx also has anti-thrombotic properties through the presence of molecules like heparan sulfate, which enhances antithrombin III activity to inhibit thrombin and coagulation factors. Additionally, it helps regulate vascular permeability, supports endothelial cell protection, and facilitates mechanotransduction by sensing blood flow and modulating responses such as nitric oxide (NO) release for vasodilation. Damage to the glycocalyx can disrupt these functions, leading to increased clot formation and vascular inflammation.'
      ],

      examAnswer: {
        formatted: [
          { type: 'paragraph', content: 'Endothelial cells regulate hemostasis by balancing anti-thrombotic and pro-thrombotic factors.' },
          {
            type: 'list',
            intro: 'Intact endothelial cells have anti-thrombotic properties:',
            items: [
              'They produce prostacyclin, or PGI2, which increases platelet cAMP levels, decreasing intracellular calcium and inhibiting platelet activation and aggregation.',
              'They produce nitric oxide, which increases cGMP levels causing vasodilation and inhibiting platelet adhesion and aggregation.',
              'They express heparan sulfate that binds and enhances antithrombin III activity, inhibiting thrombin and factor Xa to prevent clot formation.',
              'They express thrombomodulin that binds thrombin, altering its substrate specificity. The thrombin-thrombomodulin complex activates protein C, which with protein S as cofactor degrades factors Va and VIIIa, limiting coagulation.',
              'The glycocalyx surface layer prevents excessive platelet adhesion and contains heparan sulfate.'
            ]
          },
          {
            type: 'list',
            intro: 'When endothelial integrity is disrupted, pro-thrombotic activities occur:',
            items: [
              'Endothelial cells release von Willebrand factor, which facilitates platelet adhesion through GPIb/IX/V receptors.',
              'They express P-selectin recruiting platelets and leukocytes to injury sites.',
              'They release endothelin, a potent vasoconstrictor reducing blood flow and limiting blood loss.'
            ]
          }
        ],
        raw: 'Endothelial cells regulate hemostasis by balancing anti-thrombotic and pro-thrombotic factors. Intact endothelial cells have anti-thrombotic properties. They produce prostacyclin, or PGI2, which increases platelet cAMP levels, decreasing intracellular calcium and inhibiting platelet activation and aggregation. They produce nitric oxide, which increases cGMP levels causing vasodilation and inhibiting platelet adhesion and aggregation. They express heparan sulfate that binds and enhances antithrombin III activity, inhibiting thrombin and factor Xa to prevent clot formation. They express thrombomodulin that binds thrombin, altering its substrate specificity. The thrombin-thrombomodulin complex activates protein C, which with protein S as cofactor degrades factors Va and VIIIa, limiting coagulation. The glycocalyx surface layer prevents excessive platelet adhesion and contains heparan sulfate. When endothelial integrity is disrupted, pro-thrombotic activities occur. Endothelial cells release von Willebrand factor, which facilitates platelet adhesion through GPIb/IX/V receptors. They express P-selectin recruiting platelets and leukocytes to injury sites. They release endothelin, a potent vasoconstrictor reducing blood flow and limiting blood loss.'
      },
      audioUrl: '/Audio/Topic-014/LO-07.mp3'
    }
  ],
  referenceValues: [
    {
      parameter: 'platelet count',
      value: '150000-300000/μl',
      isCritical: true
    },
    {
      parameter: 'bleeding time (Ivy\'s method)',
      value: '3-5 min',
      isCritical: true
    }
  ]
};

export default topic14;
